Navtemadlin Reduces Spleen Size and Symptom Score in R/R Myelofibrosis
Navtemadlin monotherapy was safe and effective among patients with myelofibrosis who were relapsed or refractory to treatment with JAK inhibitors.
Related Articles
Comparative Analysis Shows ORR, OS Benefits With Obe-Cel in R/R B-ALL
Obe-cel showed higher response rates and longer survival vs non–CAR T therapies in adults with R/R B-ALL.
Inotuzumab Ozogamicin–Based Bridging Therapy Boosts Obe-Cel Outcomes in B-Cell ALL
The addition of inotuzumab ozogamicin to bridging therapy led to high objective response rates and sustained survival in obe-cel recipients with B-cell ALL.
Donor-Derived CAR T-Cell Therapy Yields High CR Rate With Limited OS in T-Cell Lymphoma After Allo-HSCT Relapse
A donor-derived CAR T-cell therapy produced complete remissions, but survival was limited in relapsed/refractory T-cell lymphoma.
AFM28 Shows Preliminary Activity in CD123+ Relapsed/Refractory AML
Stable disease was common in patients with CD123-positive, relapsed/refractory acute myeloid leukemia who were treated with AFM28.
Oral Decitabine/Cedazuridine Is an Effective, At-Home Treatment Option for MDS and CMML
James K. McCloskey II, MD, discusses the advantages of the oral formulation of decitabine plus cedazuridine for patients with MDS and CMML.
FELIX Analysis Suggests Consolidative SCT After Obe-Cel Does Not Improve EFS/OS in R/R B-ALL
A small sample size from an analysis of the FELIX trial suggests consolidative SCT may not be needed after obe-cel treatment in relapsed/refractory B-ALL.
Oncology Experts Preview Top Abstracts From AUA 2025
Experts highlight the top presentations to watch for at the 2025 AUA Annual Meeting.
Dr McNall-Knapp on the Efficacy of MEK Inhibition in NF1-Associated PNs
Rene Y. McNall-Knapp, MD, discusses the current treatment paradigm for pediatric and adult patients with NF1-associated PNs.
Oncology Experts Preview Abstracts to Watch at the 2025 AACR Annual Meeting
Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.
FLAURA and FLAURA2: Key Efficacy and Safety Data
Panelists discuss how osimertinib monotherapy demonstrated robust progression-free survival and overall survival benefits in FLAURA, while FLAURA2 showed that adding chemotherapy to osimertinib further improved…